Kornimate/medical-research-clean huggingface dataset:
education for prevention of melanoma in hispanic populations

Conditions: Melanoma

Summary: this clinical trial is to develop an educational platform to educate and prevent melanoma in hispanic populations. melanoma is cancer arising in the skin. educational platforms to increase the knowledge and practice of sun smart behaviors (sunscreen use, sun protective clothing use, self-skin examination) may help reduce risk of and incidence of melanoma and improve cancer survival.

primary objectives: i. develop online education platform to educate the hispanic community. ii. demonstrate improvement in knowledge and practice of sun smart behaviors. iii. determine if the education platform leads to increase visits to their medical provider and increase diagnosis of skin cancers, particularly melanoma, in our population. outline: participants complete an educational training module and complete questionnaire at baseline (before educational training module) and 3 months after completing educational training.

Eligibility criteria:
inclusion criteria: * mayo clinic patients who self-identify as hispanic or latino * age 18 and older * have an email on file with mayo clinic exclusion criteria: * all patients who do not meet inclusion criteria
intravitreal bevacizumab for the treatment of cnv in vkh disease - a prospective study

Conditions: Choroidal Neovascularization

Summary: efficacy of monthly intravitreal anti-vascular endothelial growth factor (vegf) associated to systemic immunosuppression in patients with vogt-koyanagi-harada disease and choroidal neovascularization. minimum follow-up 12 months. endpoints: 6 and 12 months of follow-up. outcome measures: improvement of va, decrease in central foveal thickness as measured by optical coherence tomography (oct) and absence of intra/subretinal fluid.

choroidal neovascularization (cnv) in vogt-koyanagi-harada (vkh) disease is associated with poor visual prognosis. several treatments have been suggested, though there is still no standard therapy. cnv diagnosis will be based on fundus biomicroscopy (presence of serous retinal detachment with or without retinal hemorrhages), fluorescein angiography (fa) (presence of early phase hyperfluorescence with late phase leakage) and oct findings (hyperreflective lesion related to a cnv complex with serous foveal detachment or intraretinal fluid with increased foveal thickness). inflammation will be considered active if anterior chamber cells or optic disc leakage in fa is observed. each patient will undergo a complete clinical exam, including best corrected visual acuity (va) (snellen charts). once active cnv is identified, a loading dose of 3 injections of iv bevacizumab will be proceeded monthly and systemic immunosuppression will be introduced or intensified. after the first 3 injections, the patient will be clinically examined and oct will be proceeded monthly. the persistence of intra/subretinal fluid in the oct will indicate one more iv bevacizumab injection. immunosuppression status evaluation will be done at 3, 6, 9 and 12 months of follow up and intensification will be done if inflammatory signs or persistence of intraretinal fluid is observed. presence of intra/subretinal fluid and manual measurement of retina central foveal thickness (cft) will be proceeded in horizontal scan by the same examiner.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with vogt-koyanagi-harada disease based on revised diagnostic criteria presented by the international committee on vkh disease in 2001; 2. presence of choroidal neovascularization identified by fundus biomicroscopy, fluorescein angiography and oct. exclusion criteria: * media opacities precluding posterior segment exam, ametropia over 5 dioptries, glaucoma (defined as a disease with characteristic damage at the optic nerve or characteristic visual field defect with compatible nerve fiber layer lesion), age related macular degeneration, impossibility to increase immunosuppression.

Keywords: choroidal neovascularization vogt koyanagi harada disease inflammatory choroidal neovascularization anti-vegf
integrated pharmacokinetics (pk)/efficacy, safety, and immunogenicity study to demonstrate similarity of jpb898, a proposed biosimilar to nivolumab, to opdivo® in combination with yervoy®

Conditions: Melanoma

Summary: the purpose of the study is to demonstrate similar pk and efficacy and to show comparable safety and immunogenicity between jpb898, opdivo-eu, and opdivo-us, all administered in combination with yervoy-eu (induction phase only), in participants with advanced (unresectable stage iii or metastatic stage iv) melanoma.


Eligibility criteria:
inclusion criteria * male or female participants must be 18 years or older. * histologically confirmed melanoma. * unresectable or metastatic melanoma measurable by computerized tomography (ct) or magnetic resonance imaging (mri). * eastern cooperative oncology group (ecog) performance status of 0 or 1. * known programmed cell death ligand 1 (pd-l1) and braf mutational status or consent to testing. * sexually active participants must agree to use effective contraception. exclusion criteria * active brain or leptomeningeal metastases unless stable for 8 weeks. * ocular melanoma. * prior active malignancy within the last year untreated or still requiring treatment. * severe and uncontrolled conditions, active hepatitis b/c, human immunodeficiency virus (hiv), or autoimmune diseases requiring systemic treatment. * previous treatment with specific immune checkpoint inhibitors, systemic anticancer therapy, or radiotherapy for melanoma.
vic regimen versus bevacizumab plus chemotherapy as first-line treatment for braf v600e-mutated advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: in this study, we compared first-line vic regimen with chemotherapy plus bevacizumab in chinese patients with initially unresectable braf v600e-mutated mcrc. the principal goal was to evaluate the safety of vic regimen, and to investigate the tumor response, the radical resectability, and the patient survival.


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤80 years old * histologically confirmed colorectal adenocarcinoma * histologically confirmed brafv600e mutated and ras wild-type * initially unresectable metastatic or local crc * ecog performance status of 0-1 and life expectancy ≥3 months * adequate hepatic, renal, and hematologic function exclusion criteria: * previously taken any targeted therapy, chemotherapy, intervention therapy, or radiotherapy for crc within 6 months * other cancers (with the exception of cervical cancer in situ and squamous cell carcinoma of the skin) within the previous 5 years.
rehabilitation after admission in intensive care unit for covid-19

Conditions: Covid19

Summary: france and especially the region "grand est" have been severely impacted by the covid-19 pandemic. the first affected patients gradually began leaving the hospitalization sector and some of them required rehabilitation before returning home. because it has only been studied for few months, covid 19 possible impairment remain unknown, especially in patients who required admission in icu and needed rehabilitation. in order to better understand the impact of the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient in rehabilitation center for post-covid-19 rehabilitation after icu. the purpose of this study was to describe the impairments and functional independency in patients addressed to a rehabilitation center after an icu stay for covid 19 and to explore the factors associated with their evolution.


Eligibility criteria:
inclusion criteria: * post-covid patient hospitalized in rehabilitation center * admission in intensive care unit with proven covid-19 disease before exclusion criteria: * patients not willing to participate via using their medical files
lung volume perception and impact of a cognitive task on ventilation in hypermobile ehlers-danlos syndrome.

Conditions: Hypermobile Ehlers-Danlos Syndrome

Summary: patients with hypermobile ehlers-danlos syndrome have respiratory and proprioceptive disorders. the aim of this study is to explore whether there is an alteration in lung volume perception in patients with heds compared to healthy subjects, and whether a cognitive task can influence ventilation control differently in subjects with heds than in healthy subjects.


Eligibility criteria:
inclusion criteria (common): * more than 18 years old * understanding french inclusion criteria (heds patients): * heds diagnosis inclusion criteria (healthy subjects): * age (±5 years), gender and bmi (±2.5kg/m²) matching exclusion criteria (common): * pregnancy exclusion criteria (heds patients): * respiratory comorbidity independent of heds * previous participation in a rehabilitation programme at the clinic exclusion criteria (healthy subjects): * known respiratory or proprioceptive pathology * hypermobility (evaluated with the beighton score)
taxotere plus cisplatin versus alimta plus cisplatin in 1st line non-squamous cell type lung cancer

Conditions: Carcinoma, Non Small Cell Lung

Summary: this study is: * a multicenter, prospective, randomized, phase 3 trial. * to prove non-inferiority of taxotere/cisplatin compared to pemetrexed/cisplatin as a front line treatment of patients with non-squamous cell lung cancer. * 276 patients will be recruited.

docetaxel is being used in 60mg/m2 3 weekly dosage in japan and several east asian institutions. docetaxel 60mg/m2 and cisplatin 70 mg/m3 3 weekly regimen will be compared to pemetrexed 500mg/m2 and cisplatin 70 mg/m2 3 weekly regimen in first line nsclc with non-squamous histology.

Eligibility criteria:
inclusion criteria: * age \>= 18 years old * ecog performance status 0-2 * non-squamous cell type non-small cell lung cancer (nsclc) * stage iv, stage iiib cannot be treated with curative intent or relapsed after surgery or radiation therapy * no prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. the last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed. * no prior immunotherapy, biologic therapy * measurable lesion with response evaluation criteria in solid tumors (recist) version 1.1 * hemoglobin \>=9.0g/dl, platelet \>=100,000/ul, neutrophil \>=1,500 /ul creatinine \ =60 ml/min bilirubin \<=1.5 x upper normal limit, transaminases \<=2 x upper normal limit alkaline phosphatase \<=2 x upper normal limit * written informed consent exclusion criteria: * pregnancy, lactating woman * woman in child bearing age who refuses to do pregnancy test * moderate or greater than grade 1 motor or sensory neurotoxicity * hypersensitivity to taxane * comorbidity or poor medical conditions * other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ) * concurrent treatment with other investigational drugs within 30 days before randomization * active treatment with other anticancer chemotherapy * egfr mutation (exon 19 deletion, l858r, l861q, g719a/c/s)

Keywords: nsclc non squamous cell docetaxel pemetrexed
developing better computerised vision tests (cvtv)

Conditions: Visual Impairment; Amblyopia; Macular Degeneration; Ophthalmic Disease

Summary: clinical vision measurements usually involve printed charts with an eye care professional interpreting patient responses to generate a score. those scores determine the need for or outcome of treatment. detecting change can be improved with strict procedures/scoring, lending itself to computerisation. this in turn allows integration with electronic medical records. many eye tests could be computerised in this way. at guys and st thomas' nhs foundation trust, the investigators have developed and validated a computerised test of distance visual acuity, called complog which is now in widespread use. the investigators now want to increase the range of tests available. there is also a need to longitudinally monitor for adverse change. such monitoring must be developed to keep false positive and false negative change detection to a minimum. the aims of this two year linked program are to: part a) validate an extended range of computerised vision measurement tests against their gold standard hard copy printed equivalents. some of these tests are designed for use in children and all are meant to quantify both normal and impaired vision. patients of all ages and visual function will therefore be recruited from st thomas' hospital. the specific tests we aim to validate are logmar letter near acuity, word near acuity, letter contrast sensitivity, auckland optotypes picture acuity, low contrast letter acuity, stereoacuity and vanishing optotypes. patients will undergo test-retest measurements with up to two of these. part b) iteratively develop an application for use in home monitoring of subjects at risk of treatable vision loss due to age related macular degeneration. all computerised tests in parts a and b will be performed on prototype software. eye patients will be recruited as subjects. patients recruited to part a will undergo tests on one day for up to an hour, subjects in part b will participate for between 1 hour and two months.


Eligibility criteria:
inclusion criteria: * male and female patients attending hospital eye clinics, aged 3 - 99, inclusive. * patients able to understand the information sheet, and willing and able to give informed consent to participate. * patients with visual function ranging from normal to severely impaired. * willing and able to comply with the visual function testing protocol. * some validation studies require recruitment of disease specific groups (such as children with amblyopia or adults with age related macular degeneration). for part b of the project which aims to develop and pilot a home monitoring application, only adult (18-99 years) subjects complying with the above who also own a suitable browser device will be recruited. exclusion criteria: * unwilling or unable to comply with the visual function testing protocol. * unwilling or unable to give informed consent. * unwilling to participate. * in other research trials.

Keywords: visual acuity visual function ocular disease
homburg renal evaluation study on the clinical utility of early aki diagnosis

Conditions: Acute Kidney Injury

Summary: critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine. because it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed. this trial is investigating if the marker urinary dickkopf-3 (udkk3) allows an early prediction of a sudden decrease of kidney function.

urinary dickkopf-3 (udkk3), a stress-induced renal tubular epithelium-derived glycoprotein, has been identified as a biomarker predicting persistent kidney dysfunction. in this prospective observational trial in patients at high risk of developing acute kidney injury we will assess whether urinary dickkopf-3 serves as a predictor of acute kidney injury. patients of the intensive care units of saarland university hospital will be surveyed for up to two years after their admission to the intensive care unit. the progression of the estimated glomerular filtration rate and udkk3 will be monitored.

Eligibility criteria:
inclusion criteria: * patients treated on the intensive care units of saarland university hospital. exclusion criteria: * patients on renal replacement treatment before admission to the intensive care unit. * patients with chronic kidney disease stage ckd g3b or below. * known kidney disease. * kidney transplantation. * intoxications leading to dialysis treatment. * participation in other clinical trials.
social effects of alcohol

Conditions: Alcohol Drinking

Summary: in this study the investigator will assess the effect of a moderate dose of alcohol on emotional responses and feelings of connection during a dyadic semi-structured social interaction

the study will use a within-subject crossover design with four sessions, in which participants receive alcohol or placebo across sessions. during the four sessions, the participants will engage in a conversation with a stranger, and emotional responses and feelings of connection will be assessed.

Eligibility criteria:
inclusion criteria: * non-problem alcohol consumption of 2-20 drinks per week * high school diploma or equivalent * bmi between 19 and 26 * verbal fluency in english exclusion criteria: * high blood pressure * any medical condition requiring regular medication * individuals with a current (within the last year) dsm-iv axis 1 diagnosis * women who are pregnant or trying to become pregnant.
cardiovascular disease risk in children with type 1 diabetes mellitus

Conditions: Type 1 Diabetes

Summary: epicardial fat thickness, carotid intima-media thickness, and augmentation index from arterial stiffness indicators are increased in children with t1dm compared to the healthy control group. these results support the idea that children with t1dm present significant changes in important subclinical indicators for the development of cardiovascular disease.


Eligibility criteria:
inclusion criteria: 1. type t1dm patients 2. body mass index (bmi) between the 5th and 85th percentile according to age and gender 3. having t1dm for at least 2 years 4. ages 8-18 years exclusion criteria: 1. having any chronic diseases other than t1dm 2. presence of a congenital and/or acquired heart disease, hypertension etc.
a prospective randomized study comparing the adenoma detection yield of sc, ai and combined ai and g-eye®

Conditions: Colorectal (Colon or Rectal) Cancer; Adenoma

Summary: this is a multicenter, 3-arm, randomized, open-label study. subjects referred to colonoscopy for screening or surveillance will be randomized in a 2:5:5 into one of the following arms: (i) standard colonoscopy (ii) artificial intelligence aided colonoscopy (gi genius™) (iii) combined artificial intelligence aided colonoscopy (gi genius™) and g-eye® balloon aided colonoscopy

this is a multicenter, 3-arm, randomized, open-label study. subjects referred to colonoscopy for screening or surveillance will be randomized in a 2:5:5 into one of the following arms: (i) standard colonoscopy (ii) artificial intelligence aided colonoscopy (gi genius™) (iii) combined artificial intelligence aided colonoscopy (gi genius™) and g-eye® balloon aided colonoscopy study aim is to compare the adenoma detection yield, expressed by adenoma per colonoscopy (apc), of these 3 arms.

Eligibility criteria:
inclusion criteria: 1. patients of age ≥ 45 years old 2. referred to colonoscopy for screening or surveillance colonoscopy (history of adenoma resection) 3. the patient must understand and provide written consent for the procedure. exclusion criteria: 1. subjects with inflammatory bowel disease 2. subjects with a personal history of polyposis syndrome 3. subjects with suspected chronic stricture potentially precluding complete colonoscopy 4. subjects with diverticulitis or toxic megacolon 5. subjects with a history of radiation therapy to abdomen or pelvis 6. pregnant or lactating female subjects 7. subjects who are currently enrolled in another clinical investigation. 8. subjects with current oral or parenteral use of anticoagulants, not considered eligible by the investigator. 9. subjects with recent (within the last 3 mounts) coronary ischemia or cva (stroke) 10. any patient condition deemed too risky for the study by the investigator 11. previous colonic surgery (except for appendectomy)
the safety, efficacy, and tolerability of microbial ecosystem therapeutic-2 in people with major depression and/or generalized anxiety disorder

Conditions: Depression, Anxiety

Summary: this study will measure the effects of met-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.

this study will measure the effects of met-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.

Eligibility criteria:
inclusion criteria: 1. able to provide informed consent. 2. not pregnant 3. willing to participate in follow up as part of the study 4. diagnosis of mdd and/or gad by mini 5. current depressive episode with a madrs score of ≥15 or current gad episode with gad-7 score of ≥8. 6. able to understand and comply with the requirements of the study 7. able to provide stool and blood samples. exclusion criteria: 1. history of chronic diarrhea 2. need for regular use of agents that affect gi motility (narcotics such as codeine or morphine, agents such as loperamide or metoclopramide) 3. colostomy 4. elective surgery that will require preoperative antibiotics planned within 6 months of enrolment 5. pregnant, breastfeeding, or planning to get pregnant in the next 6 months 6. any condition for which, in the opinion of the investigator, the participant should be excluded from the study. 7. current use of any antidepressant/antianxiety drug (eligible to participate after a 4-week washout period) 8. use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a 1-month washout period) 9. history of alcohol or substance dependence in the past 6 months 10. daily use of probiotic product in the past 2 weeks (may be eligible to participate after a 2-week washout period) 11. use of any type of laxative in the last 2 weeks. 12. consumption of products fortified in probiotics 13. high suicidal risk, as measured by madrs item 10 score more than 3 (or 4) 14. current psychotic symptoms 15. bipolar depression 16. history of epilepsy or uncontrolled seizures 17. immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired immune deficiency syndrome \[aids\], lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants) 18. unstable medical conditions or serious diseases/conditions (e.g. cancer, cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.) 19. the use of natural health products (natural health products \[nhps\]; e.g. st. john's wort, passion flower, etc.) that affect depression 20. history of electroconvulsive therapy (ect)